Australia · Delayed Price · Currency is AUD Syrah Resources Earnings Call Transcripts
Fiscal Year 2026
-
Liquidity is set to reach $178 million after recent equity raising, with no repayments due for three years. Balama and Vidalia operations are ramping up, supported by strong sustainability credentials and favorable U.S. policy, though market and policy uncertainties remain.
Fiscal Year 2025
-
Balama production and sales rebounded strongly, with robust ex-China demand and improved operational metrics. Policy changes in the U.S. are expected to support further growth, while Vidalia's commercial ramp-up depends on upcoming regulatory clarity.
-
Balama operations ramped up post-outage, achieving strong sales and improved pricing, while Vidalia advanced technical qualification and secured a $12M tax credit. Cash balance reached $87M after a $44M equity raise, with U.S. policy shifts supporting future growth.
-
Q1 2025 saw no Balama production due to protests, but Vidalia advanced in customer qualification and signed a new offtake. Cash burn was minimized, with $66M in cash and strong U.S. policy support for ex-China supply. Commercial sales from Vidalia are expected in 2025.
Fiscal Year 2024
-
Q4 2024 saw severe operational disruptions at Balama and ongoing qualification at Vidalia, with cash burn minimized and liquidity supported by a DFC loan. Market and policy volatility, especially regarding China, continues to impact outlook, but progress on U.S. tax credits and sustainability credentials positions the company for future growth.
-
Q3 2024 saw continued EV growth but significant volatility in battery and graphite markets, with China dominating supply and policy uncertainty delaying offtake agreements. A $150M DFC loan was secured, supporting liquidity, while Balama and Vidalia operations focused on readiness and qualification.
-
U.S. policy changes have delayed incentives for non-Chinese graphite, impacting near-term sales and extending qualification timelines. Operational progress continues at Balama and Vidalia, with Vidalia sales now expected from early 2025 and cost-saving measures underway.